Table 3.
Changes in TBRmax open label extension
Mean (p-value1) | |
---|---|
| |
Global change baseline compared to end of open label extension | |
Difference | −0.08 (0.002) |
% change (95% CI) | −3.80% (−6.40%, −1.19%) (0.005) |
| |
Global change start of adalimumab compared to end of open label extension | |
Difference | −0.02 (0.538) |
% change | 0.02% (−2.85%, 2.90%) (0.987) |
One sample t-test
(statistically significant findings bolded)